Avidity Biosciences Announces Positive Results for AOC 1044 in DMD Treatment
Friday, 9 August 2024, 13:05
Avidity Biosciences' Second Quarter 2024 Highlights
Avidity Biosciences has released its latest financial results, showcasing promising data in the fight against Duchenne Muscular Dystrophy (DMD).
Key Data Points:
- 25% increase in dystrophin production observed with AOC 1044.
- Reduction of creatine kinase levels to near normal ranges.
- Results are based on the ongoing Phase 1/2 clinical trial.
These milestones highlight Avidity's commitment to developing effective treatments for DMD and signal hope for patients and families affected by this condition.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.